Advertisement
News
Advertisement

MultiCell Announces Results of Shareholders' Meeting

Tue, 08/14/2012 - 1:00pm
Bio-Medicine.Org

SAN DIEGO, Aug. 14, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTCBB: MCET.OB), a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer, announced the results from its annual shareholders meeting held Friday, August 10, 2012 in San Diego, CA.

Jerry Newmin, Chairman and CEO, welcomed attendees, introduced the board of directors, officers and guests, and conducted the meeting. Shareholders ratified all items on the proxy statement including:

  1. The election of Thomas A. Page, Stephen Chang, W. Gerald Newmin, Tony Altig and Edward Sigmond as Directors for a one-year term; 
  2. The ratification of Hanson, Barnett and Maxwell as independent public accountants; 
  3. An increase in the authorized shares of the company's common stock.

The results of the meeting can be found on Form 8-K that was filed with the SEC on August 13, 2012.

After the formal portion of the meeting, Martin Schroeder of the Emmes Group, consultant to MultiCell, discussed product development priorities and progress for the past year. Mr. Newmin addressed shareholder questions including the continuing efforts to build shareholder value.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimat
'/>"/>

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading